
A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.

A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.

A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.

Results from Eli Lilly's phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.

Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.

In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.

A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.

Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).

Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.

Interim phase 1b data showed that cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.

Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.

Amanda L. Piquet, MD, reviews 1-year KYSA-8 findings, highlighting sustained clinical improvements and safety outcomes with miv-cel in patients with stiff person syndrome.

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed open-label extension data from the phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 6 minutes]

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

The president and founder of the Stuttering Treatment and Research Society (STARS) discussed highlights from the society's 2026 conference, its new interdisciplinary consensus guidelines, and the next steps for stuttering care. [WATCH TIME: 5 minutes]

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

The director of the Pediatric Neuromuscular Program at UCSF Benioff Children’s Hospital San Francisco discussed 2-year findings from the phase 2/3 VIBRANCE-MG study of nipocalimab in adolescents with generalized MG. [WATCH TIME: 6 minutes]

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

The professor of applied neuroimaging at the University of Edinburgh discusses how emerging genetic and vascular mechanisms are opening new therapeutic avenues beyond traditional risk factor management in cerebral small vessel disease. [WATCH TIME: 3 minutes]

The professor of applied neuroimaging at the University of Edinburgh discusses emerging imaging, blood-based, and functional biomarkers for tracking cerebral small vessel disease progression and evaluating treatment response. [WATCH TIME: 3 minutes]

At MSToronto 2026, investigators applied machine learning to health records, retinal scans, and blood samples to flag multiple sclerosis and neuromyelitis optica spectrum disorder years before diagnosis or disability worsening, and identified the symptoms and conditions that tend to come first.

Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.

The Editor-in-Chief of the Journal of the American Heart Association discussed what journal editors look for in stroke research submissions, how AI and open access are reshaping publishing, and the equity gaps that still exist for researchers in lower-income countries.

At MSToronto 2026, researchers showed deep learning models that extract more from routine MRI scans than volume measures alone, and clinicians described uses beyond imaging, but speakers warned that most published MS models have never been tested outside the center that built them.

The editor-in-chief of the Journal of the American Heart Association discusses what editors prioritize in research manuscripts, common submission mistakes, and strategies for improving publication readiness. [WATCH TIME: 4 minutes]